Literature DB >> 6188627

Changes in cell surface glycoproteins on non-differentiating L6 rat myoblasts selected for resistance to concanavalin A.

C L Parfett, J C Jamieson, J A Wright.   

Abstract

Four independently selected conA-resistant, non-differentiating rat L6 myoblast cell lines and their parental wild-type populations were examined for cell surface alterations. [3H]conA-binding studies indicated that the variant myoblasts bound significantly less lectin than wild-type cells at 4 and at 37 degrees C. Scatchard analysis revealed two general types of binding sites (high and low affinity sites) on wild-type cells; the variants appeared to be deficient in the high affinity sites. These changes in conA binding probably play an important role in determining the conA-resistant phenotype. Lectin-binding results could be significantly modified by altering the composition of the serum in the growth medium used to culture myoblasts prior to performing binding experiments, suggesting the existence of productive and non-productive lectin-binding sites on the cell surface. SDS slab gel electrophoresis of [3H]mannose-labelled surface membranes prepared from variant and wild-type cells showed that several glycoproteins of the conA-resistant myoblasts were defective in mannosylation. The conA-binding abilities of a pronase digest of one of these altered regions from variant separations, with a molecular weight of 44500 D, was found to contain glycopeptides with reduced affinity for the lectin, supporting the idea that variant membranes are deficient in a set of high affinity lectin-binding sites. Studies on [GDP-14C]mannose incorporation into lipid by membranes from variant and wild-type myoblasts indicated that the biosynthetic lesion likely involved a mannosyl transferase enzyme directly, rather than a lack of free dolichol-PO4. These studies link conA resistance, cell surface glycoprotein alterations, and defective mannosyl transferase activity with the inability to carry out normal cellular differentiation to form multinucleated myotubes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6188627     DOI: 10.1016/0014-4827(83)90420-2

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

1.  Characterization of deoxyguanosine-resistant hypoxanthine-guanine phosphoribosyltransferase(-)metastatic variants altered in soybean-agglutinin-binding properties and cell-surface glycoproteins.

Authors:  J E Damen; M A Spearman; A H Greenberg; J A Wright
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Studies on the effect of mevinolin (lovastatin) and mevastatin (compactin) on the fusion of L6 myoblasts.

Authors:  R S Belo; J C Jamieson; J A Wright
Journal:  Mol Cell Biochem       Date:  1993-09-22       Impact factor: 3.396

3.  Studies on the effect of ketoconazole on the fusion of L6 myoblasts.

Authors:  S Wayne; J C Jamieson; M A Spearman; J A Wright
Journal:  Mol Cell Biochem       Date:  1990-02-09       Impact factor: 3.396

4.  Glycosphingolipid biosynthesis during myogenesis of rat L6 cells in vitro.

Authors:  K C Leskawa; R E Erwin; P E Buse; E L Hogan
Journal:  Mol Cell Biochem       Date:  1988-09       Impact factor: 3.396

5.  Inhibition of myoblast fusion by the glucosidase inhibitor N-methyl-1-deoxynojirimycin, but not by the mannosidase inhibitor 1-deoxymannojirimycin.

Authors:  P C Holland; A Herscovics
Journal:  Biochem J       Date:  1986-09-01       Impact factor: 3.857

6.  Tunicamycin depresses P-glycoprotein glycosylation without an effect on its membrane localization and drug efflux activity in L1210 cells.

Authors:  Mário Sereš; Dana Cholujová; Tatiana Bubenčíkova; Albert Breier; Zdenka Sulová
Journal:  Int J Mol Sci       Date:  2011-11-10       Impact factor: 5.923

7.  Human carcinoembryonic antigen, an intercellular adhesion molecule, blocks fusion and differentiation of rat myoblasts.

Authors:  F J Eidelman; A Fuks; L DeMarte; M Taheri; C P Stanners
Journal:  J Cell Biol       Date:  1993-10       Impact factor: 10.539

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.